| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Former Director | Director | Chief Executive Officer +1 more
1 company
Rosty Raykov is Former Director at FENC. Rosty Raykov's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.3M at current prices.
Our model assigns Rosty Raykov a middling insider score of 51/100, based on 39 past trades. Over a 12-month horizon, 20.7% of those trades were profitable, with an average 12-month return of -14.8%.
The FENC filings lean toward selling, a net 405,368 shares.
Rosty Raykov has 67 Form 4 filings on record from February 2018 to August 2026, all as Former Director at Fennec Pharmaceuticals (FENC), 2018–2026.
The 105 reported transactions were 44 open-market sales, 29 stock awards, 15 option exercises and 9 option or other derivative awards, plus smaller numbers of other types.
Counted by filing, the open-market trades come to no purchases and 36 sales worth about $3.8M.
The largest open-market sale was 88,583 shares of FENC at an average $10.82 on April 5, 2024, about $959K. Twelve months later FENC was down 51%.
29 of the 35 sales since April 2023 were made under a Rule 10b5-1 trading plan; the other 6 were not.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | FENC Fennec Pharmaceuticals Inc. | Former Director | Sell10b5-1 | 10,000 | $12.11 | $121,100.00 | -7.4% | - | - | |
| Aug 3, 2026 | FENC Fennec Pharmaceuticals Inc. | Former Director | Sell10b5-1 | 10,000 | $9.58 | $95,800.00 | -7.1% | +14.2% | - | |
| Jul 1, 2026 | FENC Fennec Pharmaceuticals Inc. | Former Director | Sale+OE10b5-1 | 9,599 | $10.41 | $99,925.59 | -6.5% | +4.4% | - | |
| Jun 1, 2026 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 9,747 | $9.62 | $93,766.14 | -7.0% | +25.0% | - | |
| May 1, 2026 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 10,781 | $6.47 | $69,753.07 | -8.2% | +51.5% | - | |
| Apr 1, 2026 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 10,946 | $6.31 | $69,069.26 | -8.8% | +67.7% | - | |
| Mar 2, 2026 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 10,079 | $8.36 | $84,260.44 | -8.8% | +20.5% | - | |
| Feb 2, 2026 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 10,349 | $7.76 | $80,308.24 | -9.5% | -15.1% | - | |
| Jan 2, 2026 | FENC Fennec Pharmaceuticals Inc. | Director | Sale+OE10b5-1 | 10,312 | $7.60 | $78,371.20 | -10.5% | -16.4% | - | |
| Dec 5, 2025 | FENC Fennec Pharmaceuticals Inc. | Director | Sell10b5-1 | 10,000 | $7.54 | $75,400.00 | -11.4% | +5.0% | - |